Sarah Howell speaks to Proactive London after receiving a £ 2.8 million grant from Innovate UK to support Phase II development of AT247, an ultra-fast acting insulin product candidate. Howell explains how this treatment is based on Arecor’s proprietary Arestat technology platform.
AT247, the lead product in the next generation rapid insulin pipeline, is focused on transforming the lives of people with type 1 diabetes by enabling better glucose control.
Add related topics to MyProactive
Create your account: log in and find out about news and events
NO INVESTMENT ADVICE
The company is a publisher. You understand and agree that no content posted on the Site is a recommendation that any particular security, portfolio, transaction, or investment strategy …
In return for publishing services performed by the Company on Arecor’s behalf, including Arecor’s promotion of content on the Website by the Company, the Company receives from this issuer …
For our full disclaimer, click here